

# Diamet®

Metformin XR 500 + Glibenclamide 5

**Synergic Effect** on glycemic control

## Rational Combination

- Increase Insulin Sensitivity and Secretion
- Significantly more effective than **Metformin** or **Glibenclamide** alone
- The only available combination containing **Metformin extended release** and **Glibenclamide**.
- **BID** dosages enhancing patient compliance.



Before prescribing please consult physicians' circular.


® Registered trade name

Diamet® manufactured by **BPI**




**CE GMP**

Benta Pharma Industries - Dbayeh, Lebanon



# Diamet®

Metformin XR 500 + Glibenclamide 5



**A Rational Combination for Winner Formulation**



BENTA PHARMA INDUSTRIES

# Diamet<sup>®</sup>

Metformin XR 500 + Glibenclamide 5

# Diamet<sup>®</sup>

Metformin XR 500 + Glibenclamide 5

## The rational association

Diamet targets two Endocrine defects:  
**Insulin Resistance & Insulin Secretion**

**logical formulation**

**Metformin**

**Glibenclamide**

increases

increases

**Insulin Sensitivity**


**Insulin Secretion**

**Winner Duo  
in One Tablet**


## The rational combination

**Metformin and Glibenclamide is:**

**Significantly more effective in reducing HbA<sub>1c</sub> than Metformin or Glibenclamide alone<sup>1</sup>**



**Significantly more effective in reducing fasting plasma glucose than Metformin or Glibenclamide alone<sup>1</sup>**



Reference: 1. Tosi et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double blind, comparative study. Metabolism, vol 52, No 7 (July), 2003; pp 862-867.